Abstract
Fexofenadine hydrochloride (FEX), a second generation H1-receptor antagonist, is mainly eliminated from the liver into bile in unchanged form. Recent studies have shown that FEX can be accepted by human MDR1 (P-glycoprotein), OATP1A2 [organic anion-transporting polypeptide (OATP)-A, and OATP2B1 (OATP-B)] expression systems. However, other transporters responsible for the hepatic uptake of FEX have not yet been identified. In the present study, we evaluated the contribution of OATP family transporters, namely OATP1B1 (OATP2/OATP-C), OATP1B3 (OATP8), and OATP2B1 (OATP-B), to FEX uptake using transporter-expressing HEK293 (human embryonic kidney) cells. The uptake of FEX in OATP1B3-expressing cells was significantly greater than that in vector-transfected cells. On the other hand, OATP1B1- or OATP2B1-mediated uptake of FEX was not statistically significant. OATP1B3-mediated transport could be explained by a one-saturable component with a Michaelis constant (Km) of 108 ± 11 μM. The inhibitory effect of FEX on the uptake of estrone-3-sulfate (E1S), cholecystokinin octapeptide (CCK-8), and 17β-estradiol-17β-d-glucuronide (E217βG) was also examined. Both OATP1B1- and OATP1B3-mediated E217βG uptake was inhibited by FEX. The Ki values were 148 ± 61 and 205 ± 72 μM for OATP1B1 and OATP1B3, respectively. FEX also inhibited OATP1B3-mediated CCK-8 uptake and OATP1B1-mediated E1S uptake with a Ki value of 83.3 ± 15.3 and 257 ± 84 μM, respectively, suggesting that FEX could not be used as a specific inhibitor for OATP1B1 and OATP1B3, although FEX was preferentially accepted by OATP1B3. In conclusion, this is, to our knowledge, the first demonstration that OATP1B3 is thought to be a major transporter involved in hepatic uptake of FEX in humans.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.105.004622.
-
ABBREVIATIONS: OATP, organic anion-transporting polypeptide; HEK, human embryonic kidney; AUC, area under the plasma concentration curve; FEX, fexofenadine hydrochloride; E1S, estrone-3-sulfate; CCK-8, cholecystokinin octapeptide; E217βG, 17β-estradiol-17β-d-glucuronide; LC/MS, liquid chromatography/mass spectrometry.
- Received March 7, 2005.
- Accepted July 12, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|